LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies.
Katherine K SlemmonsSanjit MukherjeePaul MeltzerJames W PurcellLee J HelmanPublished in: Pediatric blood & cancer (2020)
Overall, LRRC15-directed ADCs are a promising new avenue for OS treatment.